AuroMedics Ranitidine Tablets Recall: Empty Bottles Risk
AuroMedics Pharma recalls 150mg Ranitidine tablets due to empty bottles in one lot. Consumers should check NDC 55910-092-79 and lot number NBSB19001DA3 for affected products.
Lower-risk recall
CGMP DEVIATIONS: One lot of Ranitidine Tablets USP, 150 mg is being recalled because some bottles were empty.
Contact the company
What happened, in plain English
AuroMedics Pharma is recalling 150mg Ranitidine tablets that were found to have empty bottles in one specific lot. This could mean the medication is ineffective or potentially unsafe for users. Read more at govinfonow.com/recall/37917-auromedics-ranitidine-tablets-recall-empty-bottles-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/37917-auromedics-ranitidine-tablets-recall-empty-bottles-risk · Updated October 5, 2026 · FDA enforcement record: FDA #D-0166-2020
Cite this page
“AuroMedics Ranitidine Tablets Recall: Empty Bottles Risk.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/37917-auromedics-ranitidine-tablets-recall-empty-bottles-risk. Based on FDA recall #D-0166-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0166-2020%22&limit=1).
Why it’s dangerous
The recall is due to CGMP deviations where some bottles were empty. This means the medication may not be effective or could pose a risk of improper dosing if the user assumes the tablets are present when they are not.
Who’s affected
People who own or use the recalled 150mg Ranitidine tablets from the specific lot (NDC 55910-092-79, Lot #: NBSB19001DA3) are affected. Those with the medication may experience ineffective treatment.
How to tell if you have this one
Check for the NDC code 55910-092-79 and lot number NBSB19001DA3 on the product label. The tablets were distributed by Dolgencorp, LLC in Goodlettsville, TN, made in India.
- Brand
AuroMedics- Category
Drug
What to do — step by step
Check Product Label
Look for the NDC code 55910-092-79 and lot number NBSB19001DA3 on the tablet packaging.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 44 days after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0166-2020 (September 23, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0166-2020 to see it in context.
- Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.